BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Down 5.4% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. (BMRN) is a biotechnology company focused on developing innovative therapies for rare genetic diseases. Today, the stock experienced a significant bearish movement in the market.

Why is BioMarin Pharmaceutical Inc. going down?

BMRN stock is down 5.4% on Mar 18, 2026 13:45

• The halt of mid-stage trials for the bone disorder treatment, Voxzogo, due to safety concerns like hip joint slippage in patients, led to a 4% drop in BioMarin's shares.
• The discontinuation of dosing and enrollment in Phase 2 trials for Voxzogo targeting various disorders due to slipped capital femoral epiphysis (SCFE) events introduced uncertainty and negatively impacted the stock.
• The competition in the achondroplasia indication, with the FDA approval of Ascendis Pharma's Yuviwel, added pressure on BioMarin as it halted studies for certain disorders, affecting investor confidence and contributing to the bearish movement.
• Despite being considered a compelling value investment opportunity with strong financial health and profitability metrics, the negative developments in the Voxzogo trials overshadowed the potential growth prospects, resulting in the stock's decline.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

[Form 4] BIOMARIN PHARMACEUTICAL INC Insider Trading Activity

BioMarin Pharmaceutical executive Charles Greg Guyer reported receiving new equity awards and a tax-related share withholding. On March 16, 2026, he was granted stock options for 35,680 shares and 14,990 restricted stock units. Additionally, 9,109 shares were withheld on March 13, 2026, to cover tax obligations.

https://www.stocktitan.net/sec-filings/BMRN/form-4-biomarin-pharmaceutical-inc-insider-trading-activity-94c91dcf1967.html

BioMarin stops mid-stage trials of bone disorder treatment

BioMarin Pharmaceutical will halt mid-stage trials for its bone disorder treatment, Voxzogo, after patients in trials for Turner Syndrome, SHOX-deficiency, and ACAN-deficiency experienced hip joint slippage. The company's shares dropped 4% following the announcement. BioMarin plans to continue testing the drug for Noonan syndrome and unexplained short stature, while Voxzogo remains approved for achondroplasia.

https://www.reuters.com/business/healthcare-pharmaceuticals/biomarin-stops-mid-stage-trials-bone-disorder-treatment-2026-03-16/

BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ)

BioMarin Pharmaceutical's shares dropped by 4% after the company announced the discontinuation of dosing and enrollment in its Phase 2 trials for Voxzogo. This decision affects trials targeting Turner syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency, and was made due to several slipped capital femoral epiphysis (SCFE) events observed in two ongoing studies.

https://seekingalpha.com/news/4564769-biomarin-shares-drop-4-as-voxzogo-trials-are-discontinued?source=feed_sector_health_care

BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts

BioMarin has halted dosing and enrollment in three Phase 2 studies of its drug Voxzogo for Turner syndrome, SHOX-deficiency, and aggrecan-deficiency due to reports of slipped capital femoral epiphysis (SCFE) events in investigator-sponsored trials. While BioMarin's own studies and the achondroplasia trials have not shown SCFE events, this move introduces uncertainty as competition for Voxzogo in achondroplasia, its key indication, is increasing with the FDA approval of Ascendis Pharma's Yuviwel. The company will continue Voxzogo studies for Noonan syndrome and idiopathic short stature, implementing new safety measures.

https://www.fiercepharma.com/pharma/biomarin-pumps-brakes-3-voxzogo-studies-competition-drugs-flagship-achondroplasia-indication

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) appears to be a compelling value investment opportunity, identified through a "Decent Value" screen. The company exhibits attractive valuation metrics, strong financial health with low debt and high liquidity, and excellent profitability with industry-leading margins. While past EPS growth was negative, analysts project significant future growth, which could act as a catalyst for a re-rating of the stock.

https://www.chartmill.com/news/BMRN/Chartmill-44175-BioMarin-Pharmaceutical-Inc-NASDAQBMRN-Presents-a-Compelling-Value-Investment-Case

Trending Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 5.1% Today

Entergy Corporation ($ETR) Stock Forecast: Up 7.0% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Down 5.7% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 6.2% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Down 6.5% Today

Align Technology Inc. ($ALGN) Stock Forecast: Down 6.1% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.6% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.0% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.4% Today

Clean Energy Fuels Corp. ($CLNE) Stock Forecast: Up 8.1% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

24.01.2026 - BMRN Stock was down 5.5%

• BioMarin posted strong Q4 revenue surpassing forecasts and a positive full-year 2025 performance. However, the stock witnessed a bearish trend possibly due to falling short of analyst predictions on non-GAAP EPS and adjusted EBITDA.
• The FDA's rejection of BioMarin's gene therapy for hemophilia A, delaying its potential market launch, might have impacted the negative investor sentiment on the company's future revenue prospects.
• An AI analysis indicating a bleak long-term outlook and increased downside risk for BioMarin could have also influenced the downward pressure on the stock.
• In conclusion, the combination of financial performance lagging expectations and regulatory obstacles could have contributed to the bearish movement of BioMarin's stock today.

18.02.2026 - BMRN Stock was down 5.4%

• The halt of mid-stage trials for the bone disorder treatment, Voxzogo, due to safety concerns like hip joint slippage in patients, led to a 4% drop in BioMarin's shares.
• The discontinuation of dosing and enrollment in Phase 2 trials for Voxzogo targeting various disorders due to slipped capital femoral epiphysis (SCFE) events introduced uncertainty and negatively impacted the stock.
• The competition in the achondroplasia indication, with the FDA approval of Ascendis Pharma's Yuviwel, added pressure on BioMarin as it halted studies for certain disorders, affecting investor confidence and contributing to the bearish movement.
• Despite being considered a compelling value investment opportunity with strong financial health and profitability metrics, the negative developments in the Voxzogo trials overshadowed the potential growth prospects, resulting in the stock's decline.

08.03.2025 - BMRN Stock was down 6.0%

• Today's downward trend in BMRN could be a result of investors taking profits following a period of positive developments and possible overvaluation.
• While the Phase 3 trial results for Palynziq in adolescent patients were encouraging, some investors may have anticipated even better outcomes, leading to selling pressure.
• Comparisons to CSL Limited in terms of valuation might have influenced investor attitudes, prompting some to reconsider their investment allocations in pursuit of perceived better opportunities.
• In conclusion, today's market behavior for BMRN appears to reflect a mix of profit-taking, unmet high expectations, and potential shifts in investor preferences within the sector.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

27.01.2026 - BMRN Stock was up 5.2%

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

04.03.2025 - BMRN Stock was down 10.4%

• Despite positive Phase 3 results for Palynziq in lowering blood Phe levels in adolescents, BioMarin's stock saw a bearish trend.
• The market may have reacted negatively due to profit-taking by investors after a recent run-up in the stock price following the positive results.
• Investors might be concerned about the timeline and potential challenges in getting label expansion approval from health authorities despite the promising data.
• The bearish movement could also be influenced by broader market conditions or sector-specific factors impacting biotechnology stocks.

29.09.2025 - BMRN Stock was down 3.3%

• Analysts revised their forecasts for BioMarin Pharmaceutical following lower-than-expected earnings reported for the third quarter.
• Earnings for the quarter were 12 cents per share, missing the analyst consensus estimate of 37 cents per share.
• The unsatisfactory earnings likely shook investor confidence, leading to a bearish movement in the stock price.
• Investors may be worried about the company's future performance and its impact on its pipeline of therapies for rare genetic diseases.